Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells

Olga Cain, Joseph Shearer, Jayne Ellis, Valentina Fokina, Forum Shah, Jeffrey M. Gimble, Marxa L. Figueiredo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background aims: Adipose-derived mesenchymal stromal cells (ASCs) are promising tools for delivery of cytotherapy against cancer. However, ASCs can exert profound effects on biological behavior of tumor cells. Our study aimed to examine the influence of ASCs on gene expression and epigenetic methylation profiles of prostate cancer cells as well as the impact of expressing a therapeutic gene on modifying the interaction between ASCs and prostate cancer cells. Methods: ASCs were modified by lentiviral transduction to express either green fluorescent protein as a control or pigment epithelium-derived factor (PEDF) as a therapeutic molecule. PC3 prostate cancer cells were cultured in the presence of ASC culture-conditioned media (CCM), and effects on PC3 or DU145. Ras cells were examined by means of real-time quantitative polymerase chain reaction, EpiTect methyl prostate cancer-focused real-time quantitative polymerase chain reaction arrays, and luciferase reporter assays. Results: ASCs transduced with lentiviral vectors were able to mediate expression of several tumor-inhibitory genes, some of which correlated with epigenetic methylation changes on cocultured PC3 prostate cancer cells. When PC3 cells were cultured with ASC-PEDF CCM, we observed a shift in the balance of gene expression toward tumor inhibition, which suggests that PEDF reduces the potential tumor-promoting activity of unmodified ASCs. Conclusions: These results suggest that ASC-PEDF CCM can promote reprogramming of tumor cells in a paracrine manner. An improved understanding of genetic and epigenetic events in prostate cancer growth in response to PEDF paracrine therapy would enable a more effective use of ASC-PEDF, with the goal of achieving safer yet more potent anti-tumor effects.

Original languageEnglish (US)
Pages (from-to)346-356
Number of pages11
JournalCytotherapy
Volume16
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Mesenchymal Stromal Cells
Epigenomics
Prostatic Neoplasms
Conditioned Culture Medium
Neoplasms
Methylation
Real-Time Polymerase Chain Reaction
Cultured Cells
pigment epithelium-derived factor
Gene Expression
Green Fluorescent Proteins
Luciferases
Genes
Culture Media
Therapeutics
Cell Culture Techniques

Keywords

  • Adipose-derived mesenchymal stromal cells
  • Epigenetics
  • Gene expression
  • Pigment epithelium-derived factor
  • Prostate cancer

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research
  • Transplantation
  • Genetics(clinical)
  • Oncology
  • Immunology and Allergy
  • Immunology

Cite this

Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells. / Cain, Olga; Shearer, Joseph; Ellis, Jayne; Fokina, Valentina; Shah, Forum; Gimble, Jeffrey M.; Figueiredo, Marxa L.

In: Cytotherapy, Vol. 16, No. 3, 03.2014, p. 346-356.

Research output: Contribution to journalArticle

Cain, Olga ; Shearer, Joseph ; Ellis, Jayne ; Fokina, Valentina ; Shah, Forum ; Gimble, Jeffrey M. ; Figueiredo, Marxa L. / Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells. In: Cytotherapy. 2014 ; Vol. 16, No. 3. pp. 346-356.
@article{cca6a10a94724a0ea2b6a2722f2bcdc9,
title = "Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells",
abstract = "Background aims: Adipose-derived mesenchymal stromal cells (ASCs) are promising tools for delivery of cytotherapy against cancer. However, ASCs can exert profound effects on biological behavior of tumor cells. Our study aimed to examine the influence of ASCs on gene expression and epigenetic methylation profiles of prostate cancer cells as well as the impact of expressing a therapeutic gene on modifying the interaction between ASCs and prostate cancer cells. Methods: ASCs were modified by lentiviral transduction to express either green fluorescent protein as a control or pigment epithelium-derived factor (PEDF) as a therapeutic molecule. PC3 prostate cancer cells were cultured in the presence of ASC culture-conditioned media (CCM), and effects on PC3 or DU145. Ras cells were examined by means of real-time quantitative polymerase chain reaction, EpiTect methyl prostate cancer-focused real-time quantitative polymerase chain reaction arrays, and luciferase reporter assays. Results: ASCs transduced with lentiviral vectors were able to mediate expression of several tumor-inhibitory genes, some of which correlated with epigenetic methylation changes on cocultured PC3 prostate cancer cells. When PC3 cells were cultured with ASC-PEDF CCM, we observed a shift in the balance of gene expression toward tumor inhibition, which suggests that PEDF reduces the potential tumor-promoting activity of unmodified ASCs. Conclusions: These results suggest that ASC-PEDF CCM can promote reprogramming of tumor cells in a paracrine manner. An improved understanding of genetic and epigenetic events in prostate cancer growth in response to PEDF paracrine therapy would enable a more effective use of ASC-PEDF, with the goal of achieving safer yet more potent anti-tumor effects.",
keywords = "Adipose-derived mesenchymal stromal cells, Epigenetics, Gene expression, Pigment epithelium-derived factor, Prostate cancer",
author = "Olga Cain and Joseph Shearer and Jayne Ellis and Valentina Fokina and Forum Shah and Gimble, {Jeffrey M.} and Figueiredo, {Marxa L.}",
year = "2014",
month = "3",
doi = "10.1016/j.jcyt.2013.11.012",
language = "English (US)",
volume = "16",
pages = "346--356",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells

AU - Cain, Olga

AU - Shearer, Joseph

AU - Ellis, Jayne

AU - Fokina, Valentina

AU - Shah, Forum

AU - Gimble, Jeffrey M.

AU - Figueiredo, Marxa L.

PY - 2014/3

Y1 - 2014/3

N2 - Background aims: Adipose-derived mesenchymal stromal cells (ASCs) are promising tools for delivery of cytotherapy against cancer. However, ASCs can exert profound effects on biological behavior of tumor cells. Our study aimed to examine the influence of ASCs on gene expression and epigenetic methylation profiles of prostate cancer cells as well as the impact of expressing a therapeutic gene on modifying the interaction between ASCs and prostate cancer cells. Methods: ASCs were modified by lentiviral transduction to express either green fluorescent protein as a control or pigment epithelium-derived factor (PEDF) as a therapeutic molecule. PC3 prostate cancer cells were cultured in the presence of ASC culture-conditioned media (CCM), and effects on PC3 or DU145. Ras cells were examined by means of real-time quantitative polymerase chain reaction, EpiTect methyl prostate cancer-focused real-time quantitative polymerase chain reaction arrays, and luciferase reporter assays. Results: ASCs transduced with lentiviral vectors were able to mediate expression of several tumor-inhibitory genes, some of which correlated with epigenetic methylation changes on cocultured PC3 prostate cancer cells. When PC3 cells were cultured with ASC-PEDF CCM, we observed a shift in the balance of gene expression toward tumor inhibition, which suggests that PEDF reduces the potential tumor-promoting activity of unmodified ASCs. Conclusions: These results suggest that ASC-PEDF CCM can promote reprogramming of tumor cells in a paracrine manner. An improved understanding of genetic and epigenetic events in prostate cancer growth in response to PEDF paracrine therapy would enable a more effective use of ASC-PEDF, with the goal of achieving safer yet more potent anti-tumor effects.

AB - Background aims: Adipose-derived mesenchymal stromal cells (ASCs) are promising tools for delivery of cytotherapy against cancer. However, ASCs can exert profound effects on biological behavior of tumor cells. Our study aimed to examine the influence of ASCs on gene expression and epigenetic methylation profiles of prostate cancer cells as well as the impact of expressing a therapeutic gene on modifying the interaction between ASCs and prostate cancer cells. Methods: ASCs were modified by lentiviral transduction to express either green fluorescent protein as a control or pigment epithelium-derived factor (PEDF) as a therapeutic molecule. PC3 prostate cancer cells were cultured in the presence of ASC culture-conditioned media (CCM), and effects on PC3 or DU145. Ras cells were examined by means of real-time quantitative polymerase chain reaction, EpiTect methyl prostate cancer-focused real-time quantitative polymerase chain reaction arrays, and luciferase reporter assays. Results: ASCs transduced with lentiviral vectors were able to mediate expression of several tumor-inhibitory genes, some of which correlated with epigenetic methylation changes on cocultured PC3 prostate cancer cells. When PC3 cells were cultured with ASC-PEDF CCM, we observed a shift in the balance of gene expression toward tumor inhibition, which suggests that PEDF reduces the potential tumor-promoting activity of unmodified ASCs. Conclusions: These results suggest that ASC-PEDF CCM can promote reprogramming of tumor cells in a paracrine manner. An improved understanding of genetic and epigenetic events in prostate cancer growth in response to PEDF paracrine therapy would enable a more effective use of ASC-PEDF, with the goal of achieving safer yet more potent anti-tumor effects.

KW - Adipose-derived mesenchymal stromal cells

KW - Epigenetics

KW - Gene expression

KW - Pigment epithelium-derived factor

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84895086862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895086862&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.11.012

DO - 10.1016/j.jcyt.2013.11.012

M3 - Article

C2 - 24424267

AN - SCOPUS:84895086862

VL - 16

SP - 346

EP - 356

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 3

ER -